Hi guys, Welcome to the Advanced Video Search Engine, and you are watching Beyond the Horizon in Gastric Cancer: Updated Evidence on How Systemic Therapies Are Redefining Care. That video is uploaded by PeerView Oncology at 2024-02-08T11:40:13-08:00. We are promoting this video only for entertainment and educational purpose only. So, I hope you like & enjoy it. [QTdUQLJ0ftg]
| Name | Beyond the Horizon in Gastric Cancer: Updated Evidence on How Systemic Therapies Are Redefining Care |
| Video Uploader | Video From PeerView Oncology |
| Upload Date | This Video Uploaded At 08-02-2024 19:40:13 |
| Video Discription | This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZKG865. CME/MOC/NCPD/AAPA/IPCE credit will be available until January 9, 2025. Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by independent educational grants from Astellas, AstraZeneca, BeiGene, Daiichi Sankyo, Inc., and Merck & Co., Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Jaffer A. Ajani, MD, FASCO, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for American Cancer Society; Amgen Inc.; Astellas Pharma Inc.; BeiGene, Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Servier. Grant/Research Support from Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc., Delta-Fly Pharma, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Prolinx, Inc.; Taiho Pharmaceutical Co, Ltd.; Takeda Pharmaceutical Company Limited; Transcenta; and Zymeworks Inc. Honoraria from Amgen Inc.; Astellas Pharma Inc.; AstraZeneca; BeiGene, Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co, Inc.; Novartis Pharmaceuticals Corporation; Servier; and Zymeworks Inc. Co-Chair/Planner Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; EMD Serono Inc.; Geneos Therapeutics, Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Lynx Health; Merck & Co., Inc.; Mersana Therapeutics Inc.; Pfizer; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc. Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense. Stock Shareholder in Inspirna, Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below. QTdUQLJ0ftg |
| Category | Education |
| Tags | Jaffer A. Ajani MD FASCO | Yelena Y. Janjigian MD | CME | MOC | NCPD | AAPA | IPCE | meded | oncology | gastric cancer | HER2 | ERBB | HER3 | EGFR | PD-L1 | FGFR2 | FGFR-TKI | KEYNOTE-811 | DESTINY-Gastric01 | DESTINY-Gastric02 | CheckMate -649 | KEYNOTE-859 | SPOTLIGHT | GLOW | CheckMate -577 | KEYNOTE-585 | MATTERHORN | RATIONALE-305 | trastuzumab | pembrolizumab | trastuzumab deruxtecan | T-DXd | nivolumab | tislelizumab | durvalumab | zolbetuximab | bemarituzumab | zanidatamab | evorpacept | futibatinib | infigratinib |
